Publicacións en colaboración con investigadores/as de Hospital Vall d'Hebron (18)

2023

  1. (Pre)treatment risk factors for late fatigue and fatigue trajectories following radiotherapy for breast cancer

    International Journal of Cancer, Vol. 153, Núm. 9, pp. 1579-1591

  2. Genome-wide association study of treatment-related toxicity two years following radiotherapy for breast cancer

    Radiotherapy and Oncology, Vol. 187

  3. Large-scale meta-genome-wide association study reveals common genetic factors linked to radiation-induced acute toxicities across cancer types

    JNCI Cancer Spectrum, Vol. 7, Núm. 6

  4. Reply to: Comments on “(Pre)treatment risk factors for late fatigue and fatigue trajectories following radiotherapy for breast cancer”

    International Journal of Cancer

2022

  1. Development and Optimization of a Machine-Learning Prediction Model for Acute Desquamation After Breast Radiation Therapy in the Multicenter REQUITE Cohort

    Advances in Radiation Oncology, Vol. 7, Núm. 3

  2. Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study)

    Lung Cancer, Vol. 166, pp. 228-241

  3. The correlation between pre-treatment symptoms, acute and late toxicity and patient-reported health-related quality of life in non-small cell lung cancer patients: Results of the REQUITE study: Symptoms, toxicity and quality of life of lung cancer patients

    Radiotherapy and Oncology, Vol. 176, pp. 127-137

  4. Treatment time and circadian genotype interact to influence radiotherapy side-effects. A prospective European validation study using the REQUITE cohort

    eBioMedicine, Vol. 84

  5. Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer

    Radiotherapy and Oncology, Vol. 168, pp. 75-82

2021

  1. 10-Year Results of a Phase III Randomized Trial of High-Dose Radiotherapy and Risk-Adapted Androgen Deprivation in Localized Prostate Cancer

    International journal of radiation oncology, biology, physics, Vol. 111, Núm. 3, pp. S77

  2. Impact of covid-19 on patients in radiotherapy oncology departaments in Spain

    Radiotherapy and Oncology

  3. Prognostic value of testosterone castration levels following androgen deprivation and high-dose radiotherapy in localized prostate cancer: Results from a phase III trial

    Radiotherapy and Oncology, Vol. 160, pp. 115-119

2020

  1. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

    Nature Genetics, Vol. 52, Núm. 1, pp. 56-73

2019

  1. REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer

    Radiotherapy and Oncology, Vol. 138, pp. 59-67

2016

  1. Consumption of systemic antifungal agents among acute care hospitals in Catalonia (Spain), 2008-2013

    Expert Review of Anti-Infective Therapy, Vol. 14, Núm. 1, pp. 137-144

  2. Late Radiation and Cardiovascular Adverse Effects After Androgen Deprivation and High-Dose Radiation Therapy in Prostate Cancer: Results From the DART 01/05 Randomized Phase 3 Trial

    International Journal of Radiation Oncology Biology Physics, Vol. 96, Núm. 2, pp. 341-348

2015

  1. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): A randomised, controlled, phase 3 trial

    The Lancet Oncology, Vol. 16, Núm. 3, pp. 320-327

2007

  1. Risk factors for candidaemia in critically ill patients: A prospective surveillance study

    Mycoses, Vol. 50, Núm. 4, pp. 302-310